Biopôle based HAYA Therapeutics, a Swiss startup developing precision medicines has established a new laboratory space at JLABS @ San Diego, part of Johnson & Johnson Innovation’s global network of life science incubators. The biotech also closed a $5 million seed extension bringing the total amount raised for the seed round to approximately US$25 million.
The company will use the funding to grow its team in Switzerland and San Diego. HAYA’s main headquarters and laboratory facilities will remain in Lausanne. In addition the new funds will allow HAYA to advance its lead therapeutic candidate, targeting a driver of fibrosis in the heart. The therapy is being developed to treat non-obstructive hypertrophic cardiomyopathy, an orphan indication with limited treatment options. HAYA is also expanding its pipeline of lncRNA targeting anti-fibrotics using its proprietary DiscoverHAYA drug discovery engine for other indications.
The seed extension was led by Humboldt Fund, with participation from existing investors including Broadview Ventures, Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
“Over the past year, we have made tremendous progress demonstrating the validity of our lead candidate and continue to make new advances with our lncRNA drug discovery engine,” said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. “We are excited to have this additional financial support from Humboldt Fund and our existing seed investors, and look forward to starting our journey in the U.S. and join other world-leading companies in the RNA-therapeutics space.”
(Press release - ES)
Please login or sign up to comment.
Commenting guidelines